Metastatic Mucinous Adenocarcinoma of Unknown Origin Showing 68Ga-DOTATATE Uptake
- 30 October 2024
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (1) , e51-e52
Abstract
Although the use of 18F-FDG PET/CT is well established in the evaluation of adenocarcinoma, the performance of 18F-FDG PET/CT in mucinous adenocarcinoma is not consistent. 68Ga-DOTATATE uptake can be observed in some non-neuroendocrine tumors as a result of tumor blood flow and somatostatin receptor expression at different levels. For this reason, 68Ga-DOTATATE PET/CT may have a prospective role in the evaluation of mucinous adenocarcinoma. However, there is no published case of mucinous adenocarcinoma with 68Ga-DOTATATE uptake. We present a unique case of metastatic mucinous adenocarcinoma of unknown origin on 68Ga-DOTATATE PET/CT.Keywords
This publication has 8 references indexed in Scilit:
- Variants and Pitfalls in PET/CT Imaging of Gastrointestinal CancersSeminars in Nuclear Medicine, 2021
- Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatmentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CTAmerican Journal of Roentgenology, 2018
- Evaluation of the Possible Utilization of 68Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer2017
- The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal AdenocarcinomaAbdominal Radiology, 2017
- 68Ga-DOTATATE PET/CT in Nonneuroendocrine TumorsClinical Nuclear Medicine, 2017
- 18F-FDG-PET/CT of peritoneal tumorsNuclear Medicine Communications, 2017
- Usefulness of 18F-FDG PET/CT to Detect Metastatic Mucinous Adenocarcinoma Within an Inguinal HerniaNuclear Medicine and Molecular Imaging, 2015